5.65 0.12 (2.17%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 6.72 ![]() |
1-year : | 7.85 ![]() |
Resists | First : | 5.76 ![]() |
Second : | 6.72 ![]() |
Pivot price | 5.35 ![]() |
|||
Supports | First : | 4.99 ![]() |
Second : | 4.53 |
MAs | MA(5) : | 5.59 ![]() |
MA(20) : | 5.26 ![]() |
MA(100) : | 4.5 ![]() |
MA(250) : | 6.29 ![]() |
|
MACD | MACD : | 0.2 ![]() |
Signal : | 0.2 ![]() |
%K %D | K(14,3) : | 86.5 ![]() |
D(3) : | 87.5 ![]() |
RSI | RSI(14): 64.7 ![]() |
|||
52-week | High : | 10.42 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TLSI ] has closed below upper band by 18.3%. Bollinger Bands are 0.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 5.77 - 5.8 | 5.8 - 5.83 |
Low: | 5.45 - 5.49 | 5.49 - 5.53 |
Close: | 5.59 - 5.65 | 5.65 - 5.71 |
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Fri, 14 Feb 2025
Lake Street Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy Recommendation - Nasdaq
Thu, 13 Feb 2025
TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Lake Street Capital - MarketBeat
Mon, 10 Feb 2025
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock - MarketBeat
Thu, 06 Feb 2025
Trisalus Life Sciences CFO buys $33,900 in common stock - Investing.com
Mon, 03 Feb 2025
Trisalus Life Sciences Announces Key Appointments To Board Of Directors -February 03, 2025 at 05:03 pm EST - Marketscreener.com
Mon, 03 Feb 2025
TriSalus Life Sciences, Inc. Announces Drawdown of $10 Million Tranche Under Credit Agreement with Orbimed - Marketscreener.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 30 (M) |
Shares Float | 21 (M) |
Held by Insiders | 43.3 (%) |
Held by Institutions | 17.2 (%) |
Shares Short | 58 (K) |
Shares Short P.Month | 51 (K) |
EPS | -1.92 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.99 |
Profit Margin | -219.8 % |
Operating Margin | -111 % |
Return on Assets (ttm) | -133.2 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 59.7 % |
Gross Profit (p.s.) | 0.71 |
Sales Per Share | 0.81 |
EBITDA (p.s.) | -1.7 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -55 (M) |
Levered Free Cash Flow | -53 (M) |
PE Ratio | -2.95 |
PEG Ratio | 0 |
Price to Book value | -5.77 |
Price to Sales | 6.96 |
Price to Cash Flow | -3.16 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |